GLP-1 Medication Comparison Calculator

Compare Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, and Rybelsus side-by-side on weight loss outcomes, administration, half-life, mechanism, and approval status.

Share this calculator

Wegovy

semaglutide 2.4 mg

Weight ✓ GLP-1

Administration

Weekly injection

Half-life

7 days

Peak weight loss

~14.9%

Trial

68 weeks

Expected weight loss by timepoint (% body weight)
3 mo
5.9%
6 mo
10.3%
12 mo
13.8%
18 mo
14.9%

First GLP-1 approved for chronic weight management in non-diabetic adults (2021).

Zepbound

tirzepatide 5–15 mg

Weight ✓ GIP/GLP-1

Administration

Weekly injection

Half-life

5 days

Peak weight loss

~20.9%

Trial

72 weeks

Expected weight loss by timepoint (% body weight)
3 mo
6.9%
6 mo
13.4%
12 mo
19.3%
18 mo
20.9%

Dual GIP/GLP-1 receptor agonist; highest mean weight loss in pivotal trials to date (SURMOUNT-1).

Mounjaro

tirzepatide 5–15 mg

Diabetes ✓ GIP/GLP-1

Administration

Weekly injection

Half-life

5 days

Peak weight loss

~13.3%

Trial

40 weeks

Expected weight loss by timepoint (% body weight)
3 mo
5.2%
6 mo
9.3%
12 mo
12.5%
18 mo
13.3%

Same compound as Zepbound but approved for T2D; weight loss as secondary benefit. Often prescribed off-label for weight management.

Ozempic

semaglutide 0.5–2 mg

Diabetes ✓ GLP-1

Administration

Weekly injection

Half-life

7 days

Peak weight loss

~5.9%

Trial

104 weeks

Expected weight loss by timepoint (% body weight)
3 mo
2.4%
6 mo
4.1%
12 mo
5.3%
18 mo
5.9%

Approved for T2D; commonly prescribed off-label for weight management. Lower dose than Wegovy.

Saxenda

liraglutide 3 mg

Weight ✓ GLP-1

Administration

Daily injection

Half-life

13h

Peak weight loss

~8.4%

Trial

56 weeks

Expected weight loss by timepoint (% body weight)
3 mo
4.8%
6 mo
7.2%
12 mo
8%
18 mo
7.8%

First daily injectable GLP-1 approved for weight management (2014); now largely superseded by weekly injections.

Rybelsus

oral semaglutide 14 mg

Diabetes ✓ GLP-1

Administration

Daily oral

Half-life

7 days

Peak weight loss

~4.2%

Trial

84 weeks

Expected weight loss by timepoint (% body weight)
3 mo
1.5%
6 mo
2.8%
12 mo
4.2%
18 mo
4.2%

Only oral GLP-1; lower bioavailability than injectable semaglutide means less weight loss on average. Approved for T2D only.

Trial data comparison Weight loss percentages are population averages from pivotal clinical trials. Direct head-to-head comparisons between medications in the same population are limited. Individual results vary widely based on dose, adherence, diet, and activity.

Also in Weight Loss Medication

GLP-1 Cost Calculator GLP-1 Dose Schedule Calculator GLP-1 Eligibility Calculator GLP-1 Half Life Calculator GLP-1 Protein Calculator GLP-1 Weight Loss Calculator GLP-1 Weight Loss Rate Calculator

GLP-1 Medication Comparison

GLP-1 Medication Comparison — Ozempic vs Wegovy vs Mounjaro vs Zepbound

Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, and Rybelsus are GLP-1 or GIP/GLP-1 receptor agonists used for weight loss or type 2 diabetes. This GLP-1 medication comparison tool lets you compare them side-by-side on weight loss outcomes, mechanism, half-life, administration route, and approval status.

Ozempic vs Wegovy — what is the difference?

Ozempic and Wegovy both contain semaglutide — the same active molecule. The key difference is dose and indication. Wegovy uses a higher maintenance dose (2.4 mg/week) and is FDA-approved specifically for chronic weight management. Ozempic is approved for type 2 diabetes at lower doses (0.5–2 mg/week) and carries a secondary cardiovascular risk reduction indication.

Because of the higher dose, Wegovy produces significantly more weight loss (~14.9% vs ~5-6% in trial data). Cost and insurance coverage also differ substantially between the two.

Zepbound vs Wegovy — which is stronger?

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist — it activates two hormonal pathways compared to semaglutide's one. In the SURMOUNT-1 trial, Zepbound at 15 mg produced ~20.9% body weight loss at 72 weeks — the highest of any approved agent at the time. Wegovy produced ~14.9% in STEP 1 at 68 weeks.

A direct head-to-head trial (SURMOUNT-5) comparing semaglutide 2.4 mg to tirzepatide has been conducted. Tirzepatide showed greater weight loss in that comparison as well.

Mounjaro vs Ozempic and Mounjaro vs Zepbound

Mounjaro and Zepbound contain the same molecule — tirzepatide — at the same doses. Mounjaro is the brand approved for type 2 diabetes; Zepbound is approved for weight management. Clinicians sometimes prescribe Mounjaro off-label for weight loss in patients without diabetes.

Ozempic and Mounjaro were compared directly in the SURPASS-2 trial in a type 2 diabetes population. Tirzepatide at 15 mg produced greater HbA1c reduction and significantly greater weight loss than semaglutide 1 mg.

Frequently asked questions

Which GLP-1 medication is best for weight loss?

Based on current pivotal trial data, tirzepatide (Zepbound/Mounjaro) at 15 mg shows the highest mean weight loss (~20.9%) followed by semaglutide 2.4 mg (Wegovy) at ~14.9%. The best choice for an individual depends on indication, tolerability, cost, insurance coverage, and comorbidities.

 Are Ozempic and Wegovy the same drug?

Same molecule (semaglutide), different doses and indications. Wegovy (2.4 mg/week) is approved for chronic weight management. Ozempic (0.5–2 mg/week) is approved for type 2 diabetes. Higher doses in Wegovy drive its greater weight loss effect.

 Is Rybelsus (oral semaglutide) as effective as injectable semaglutide?

Rybelsus delivers semaglutide orally but with lower bioavailability (~1%). Approved for type 2 diabetes at up to 14 mg/day, it shows less weight loss than injectable Wegovy (~4% vs ~15%). Not approved for weight management.

Related

More from nearby categories

These related calculators come from the same leaf category, nearby sibling categories, or the same top-level topic.

GLP-1 Weight Loss Calculator

Project expected weight loss on Wegovy, Zepbound, Ozempic, Saxenda, or Mounjaro from your starting weight, based on pivotal clinical trial averages at 3, 6, 12, and 18 months.

Open calculator

GLP-1 Eligibility Calculator

Check whether your BMI and health conditions meet FDA label criteria for GLP-1 weight-loss medications such as Wegovy, Zepbound, and Saxenda.

Open calculator

GLP-1 Dose Schedule Calculator

Generate a personalised GLP-1 titration schedule with dated dose phases for Wegovy, Zepbound, Ozempic, Saxenda, or other medications from your first injection date.

Open calculator

GLP-1 Cost Calculator

Compare US self-pay list prices for Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, and Rybelsus on a monthly and annual basis, with insurance and savings programme notes.

Open calculator

Privacy choices

If you allow analytics, we may use Google Analytics and Microsoft Clarity to better understand how the site is used. Analytics remain off unless you accept.